Servier shared a post on LinkedIn:
“The 2024-2025 fiscal year was marked by major advances in oncology, reaffirming the Group’s commitment to developing innovations for patients with rare cancers.
Over the past year, we obtained several marketing authorizations in oncology around the world. These milestones reflect our ability to develop new therapeutic solutions for rare forms of cancer with high unmet medical needs — and to make them accessible to patients.
In addition, the Group entered into three significant partnership agreements that underscore our commitment to developing targeted oncology therapies and the value creation potential of our R&D.
Today, 8 medicines are available to healthcare professionals and patients. Our major investments in cancer are also illustrated by a robust R&D pipeline of 34 projects.
This year, we were honored to be ranked #1 in the PatientView survey by the patient organizations working with us — a recognition that encourages us to continue strengthening partnerships with patients.
Read the press release.”
Proceed to the video attached to the post.
More posts featuring Servier.